Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions.
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
04:55am, Monday, 03'rd Nov 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes.
Final Trades: Rocket Companies, Meta, Cleveland-Cliffs, Bristol Myers
01:33pm, Friday, 31'st Oct 2025
The Investment Committee give you their top stocks to watch for the second half.
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript
04:06pm, Thursday, 30'th Oct 2025
Bristol-Myers Squibb Company ( BMY ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Chuck Triano Christopher Boerner - CEO & Chairman David Elkins - Executive VP & CFO Cristia
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
02:55pm, Thursday, 30'th Oct 2025
Bristol Myers Squibb Co. (NYSE:BMY) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year.
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
01:22pm, Thursday, 30'th Oct 2025
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent
10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)
11:51am, Thursday, 30'th Oct 2025
The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
11:36am, Thursday, 30'th Oct 2025
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 30'th Oct 2025
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street
The 5 Very Best High-Yield Stocks Boomers Can Buy Now
09:14am, Thursday, 30'th Oct 2025
While many seniors have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
09:11am, Thursday, 30'th Oct 2025
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.63 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.8 per share a year ago.
Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.
07:32am, Thursday, 30'th Oct 2025
While total revenue grew in the quarter, competition weighed on the drugmaker's legacy portfolio.
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
07:11am, Thursday, 30'th Oct 2025
Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales
07:03am, Thursday, 30'th Oct 2025
Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from g
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
06:59am, Thursday, 30'th Oct 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025.
